Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
(2020) published a validated detection assay specific to LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I in athlete samples
In the NETTER-I phase III clinical trial, it was demonstrated that 4 cycles of PRRT with [ 177 Lu]Lu-[DOTA,Tyr 3 ]-octreotide ([ 177 Lu]Lu-DOTA-TATE) in combination with octreotide LAR resulted in longer progression-free survival and higher response rates in patients with advanced midgut NETs, compared to high-dose octreotide LAR treatment alone [29]
In laboratory conditions, BPC-157 remains stable in acidic environments, supporting its proposed gut-protective role
Net-432-Gb/s/ PS-PAM transmission based on advanced DSP and single DAC for 400 G/ [PMID: 38560829] Laboratory literature summary: Net-432-Gb/s/ PS-PAM transmission based on advanced DSP and single DAC for 400 G/ IM/DD links
US$ 22.85
US$ 26.47
US$ 22.22
US$ 27.95
US$ 28.50
